Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
04/05/202313h30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
01/05/202322h29Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:NTLAIntellia Therapeutics Inc
01/05/202313h30GlobeNewswire Inc.Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) PrioritiesNASDAQ:NTLAIntellia Therapeutics Inc
27/04/202313h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
18/04/202322h50Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:NTLAIntellia Therapeutics Inc
18/04/202322h24Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:NTLAIntellia Therapeutics Inc
18/04/202322h17Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NTLAIntellia Therapeutics Inc
17/04/202322h59Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NTLAIntellia Therapeutics Inc
17/04/202322h01GlobeNewswire Inc.Intellia Therapeutics Names Bill Chase to its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
21/03/202313h25Dow Jones NewsIntellia Therapeutics Gets FDA RMAT Designation for NTLA-2002 in Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
21/03/202312h30GlobeNewswire Inc.Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
03/03/202323h35Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NTLAIntellia Therapeutics Inc
02/03/202313h00GlobeNewswire Inc.Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202322h19Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202322h11Edgar (US Regulatory)Annual Report (10-k)NASDAQ:NTLAIntellia Therapeutics Inc
23/02/202313h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
16/02/202313h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
09/02/202317h48Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:NTLAIntellia Therapeutics Inc
11/01/202313h30GlobeNewswire Inc.Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
05/01/202313h30GlobeNewswire Inc.Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key MilestonesNASDAQ:NTLAIntellia Therapeutics Inc
01/12/202211h42TipRanksHere’s Why Intellia (NASDAQ:NTLA) Stock Is Trending LowerNASDAQ:NTLAIntellia Therapeutics Inc
01/12/202203h28GlobeNewswire Inc.Intellia Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
30/11/202222h36GlobeNewswire Inc.Intellia Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:NTLAIntellia Therapeutics Inc
14/11/202222h35TipRanksChardan Capital Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
14/11/202215h45TipRanksIntellia Therapeutics (NTLA) Receives a Hold from BMO CapitalNASDAQ:NTLAIntellia Therapeutics Inc
12/11/202222h30GlobeNewswire Inc.Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
10/11/202205h27TipRanksSVB Securities Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
10/11/202205h21TipRanksAnalysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), BioMarin Pharmaceutical (BMRN) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
07/11/202222h10TipRanksAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Quest Diagnostics (DGX) and Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
07/11/202204h35TipRanksSVB Securities Keeps Their Buy Rating on Intellia Therapeutics (NTLA)NASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées